Oakes, Lyman: Is This the Model for Building European Device Companies?

Despite outstanding clinical science, Europe has historically lagged behind the US, if not in medical device innovation, at least in device company creation. A vicious cycle of few start-ups, reluctant VCs, and a poor pool of experienced managers has kept company creation from exploding. But now former merchant bankers turned serial entrepreneurs, Herb Oakes and Dick Lyman, believe they have a better formula for starting device companies in Europe.

Successful device-company creation works in a kind of virtuous circle: physicians or engineers with promising ideas find venture backers who believe in those ideas and fund the launch of a company to bring the innovation to market and who, in turn, after a certain period of time, find seasoned executives to grow the company and realize the potential of the idea.

But that virtuous circle can turn vicious if any of those pieces are missing: if physicians are reluctant to commercialize...

More from Global Vision

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.